Please enable JS


Victory in the USA

Aug 28/50SN Staff/ Victories

Thank you Advocates! FDA Issues Draft Guidance for Biosimilar Naming: A Proposed Rule that Designates Official Names and Proper Names for Certain Biological Products Your efforts are making a difference. GHLF is pleased to share that the Food and Drug Administration (FDA) released a draft guidance requiring biological products licensed under the Public Health Service […]


Victory in Illinois

Aug 03/50SN Staff/ Victories

GHLF applauds our CreakyJoints community for taking action!


Texas Pharmaceutical & Therapeutics Committee – July Meeting outcome

Jul 29/50SN Staff/ Letters and Testimony

On July 24th, the Texas Pharmaceutical and Therapeutics (P&T) Committee, a part of the Texas Health and Human Services Commission, convened to review a number of different medications and medication classes for entry onto their Preferred Drug List (PDL) of the Texas Medicaid Formulary. A medication to alleviate symptoms of opioid-induced constipation (OIC) was one […]


7/9/2015 – Teleconference with Assemblywoman Jaffee

Jul 29/50SN Staff/ Events

Assemblywoman Jaffee provided our listeners with some important advice about the power of the patient perspective. Listen to what she had to say:


5 reasons biosimilars must have distinguishable names

Jul 27/50SN Staff/ GHLF in the news

If you ask patients with severe chronic diseases, such as those with rheumatoid arthritis, cancer, or multiple sclerosis, what they believe is the most important factor in achieving a positive outcome for their condition or disease, the vast majority will say it’s the relationship they have with their physician and treatment team.